# Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

> **NCT02365584** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 43 (actual)

## Conditions studied

- Intestinal Obstruction

## Interventions

- **DRUG:** lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT02365584
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-01-16
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The study was terminated early due to insufficient recruitment.
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365584, "Quality of Life in Patients With Inoperable Malignant Bowel Obstruction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02365584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*